Desensitization With Bortezomib Before a Living Kidney Donation

• Status: Unknown status
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators plan to study the role of bortezomib for desensitizing patients awaiting a living kidney donation who have a titer of Donor Specific anti human leucocyte antigen (HLA) Antibody (DSA) between 1000 and 3000 MFI with a pilot study of 10 patients recruited in 4 hospital in FRANCE.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• Patient between 18 and 70 years old

• awaiting a living kidney donation

• but with a least one DSA titer between 1000 MFI and 3000 MFI

Exclusion Criteria:

• positive cell dependent cytotoxicity CM,

• DSA level above 3000 MFI

• and every condition that is a contre indication for bortezomib treatment